ReviewiLIVER2023
Advances in diagnostic ultrasound techniques for assessing liver steatosis in nonalcoholic fatty liver disease.
Review in iLIVER, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Applicability of attenuation imaging and shear wave elastography in non-invasive assessment of liver steatosis and fibrosis in adult patients.Polish journal of radiology · 2026Article
- Hyperferritinemia and the Risk of Liver Fibrosis and Liver-Related Events in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.Medicina (Kaunas, Lithuania) · 2025Article
- Epicardial Adipose Tissue and Liver Fibrosis in Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Liver Disease.Reviews in cardiovascular medicine · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Patients-The Relationship with Platelets Indicators.Medicina (Kaunas, Lithuania) · 2024Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of nonalcoholic fatty liver disease (NAFLD), a common chronic liver disease, is increasing yearly. With increasing degrees of liver steatosis, NAFLD can progress to varying degrees of hepatic fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC), with a concomitant increase in the risk of metabolic syndrome and cardiovascular disease. Therefore, early diagnosis and accurate assessment of NAFLD are particularly significant. Although liver biopsy is regarded as the standard for evaluating the degree of hepatic steatosis in NAFLD, it is not frequently utilized due to its invasiveness. Ultrasound technology as a noninvasive diagnostic method has the advantages of operating simplicity and economy. It can effectively diagnose and assess the disease of NAFLD. This article mainly summarizes the current status and progress of research on the assessment of NAFLD and liver steatosis by two main types of ultrasound techniques, semi-quantitative and quantitative ultrasound, as well as other emerging techniques, and briefly describes the strengths and limitations of B-mode ultrasound, controlled attenuation parameters (CAP), and attenuation imaging (ATI) in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.